The aim of this trial is to assessthe effectiveness and  toxicityof adjuvant post-operative RT vs combined RT and CT(5-FU plus levamisole) in  patientswith TNM stage II-IIIresectable rectal cancer (pT3-4 , pN0 ,  M0 , pTl-4 , pNl-3 , M0) .
Within 42 days from surgery , patients randomized in Arm I receive  RT (50 Gy) in daily fractions of 2 Gy , 5 days/wk for 5 wk , to tumour bed and loco-regional lymph-nodes (internal iliac and presacral nodes)  with four portals (LL and AP) .
Patients randomized in Arm II begin with the first cycle of 5-FU (450 mg/sqm/d iv bolus on days 1-5) plus ievamisole (150 mg/d orally on  days1-3) .
